Florian Lordick, Professor of Medicine at the University of Leipzig, shared a post on LinkedIn:
“Preliminary data from a phase Ib Clinical Trial presented at ESMOGI25 suggest that a triple combination of givastomig (a first-in-class claudin [CLDN]18.2/4-1BB bispecific antibody), nivolumab and mFOLFOX has promising activity and an acceptable safety profile in patients with HER2-negative, CLDN18.2-positive, metastatic GastroEsophageal adenocarcinoma.
Responses occurred irrespective of PDL1 combined positive score and in patients with <75% CLDN18.2.
There were no dose-limiting toxicities and the maximum tolerated dose was not reached.
Read the full article in the ESMO Daily Reporter.”
More posts featuring Florian Lordick.